CLEARSIDE BIOMEDICAL INC (CLSD) Stock Price, Forecast & Analysis
NASDAQ:CLSD • US1850632035
CLSD Key Statistics, Chart & Performance
The current stock price of CLSD is 0.41 USD. In the past month the price decreased by -89.12%. In the past year, price decreased by -97.4%.
CLSD Technical Analysis
CLSD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSD. Both the profitability and financial health of CLSD have multiple concerns.
CLSD Financial Highlights
Over the last trailing twelve months CLSD reported a non-GAAP Earnings per Share(EPS) of -5.19. The EPS increased by 19.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLSD Forecast & Estimates
11 analysts have analysed CLSD and the average price target is 61.2 USD. This implies a price increase of 14826.83% is expected in the next year compared to the current price of 0.41.
For the next year, analysts expect an EPS growth of 56.93% and a revenue growth 102.46% for CLSD
CLSD Ownership
CLSD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.19 | 981.56B | ||
| JNJ | JOHNSON & JOHNSON | 20.93 | 589.194B | ||
| MRK | MERCK & CO. INC. | 22.51 | 295.956B | ||
| PFE | PFIZER INC | 9.24 | 156.186B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 121.86B | ||
| ZTS | ZOETIS INC | 18.6 | 55.368B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.73 | 25.86B | ||
| VTRS | VIATRIS INC | 6.23 | 18.186B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.06 | 12.317B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.93 | 9.222B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLSD
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005 US
CEO: George Lasezkay
Employees: 32
Phone: 16782703631
CLEARSIDE BIOMEDICAL INC / CLSD FAQ
What does CLSD do?
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Can you provide the latest stock price for CLEARSIDE BIOMEDICAL INC?
The current stock price of CLSD is 0.41 USD. The price decreased by -26.96% in the last trading session.
Does CLSD stock pay dividends?
CLSD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLSD stock?
CLSD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CLSD stock?
CLSD stock is listed on the Nasdaq exchange.
What is CLEARSIDE BIOMEDICAL INC worth?
CLEARSIDE BIOMEDICAL INC (CLSD) has a market capitalization of 2.14M USD. This makes CLSD a Nano Cap stock.
When does CLEARSIDE BIOMEDICAL INC (CLSD) report earnings?
CLEARSIDE BIOMEDICAL INC (CLSD) will report earnings on 2026-03-25, after the market close.